The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Behcet Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Behcet Syndrome


High impact information on Behcet Syndrome


Chemical compound and disease context of Behcet Syndrome


Biological context of Behcet Syndrome


Anatomical context of Behcet Syndrome


Gene context of Behcet Syndrome

  • In Behçet disease, besides the decrease in tPA synthesis, high PAI levels also can affect tPA decrease and lead to inhibition of fibrinolytic activity [24].
  • We also assessed the possible involvement of VEGF in ocular Behçet's syndrome or in disease activity [25].
  • Significantly higher titres of IFN-gamma were produced by MNC from patients with Behçet's syndrome than MNC from patients with other inflammatory diseases (P = 0.005), hospital controls (P = 0.036) or healthy controls (P = 0.009) [26].
  • We previously demonstrated the possible involvement of proinflammatory cytokines [tumor necrosis factor (TNF)-alpha, soluble interleukin-2 receptor (sIL-2R), interleukin (IL)-6 and IL-8], nitric oxide (NO) and adrenomedullin in the etiopathogenesis of Behçet's syndrome [25].
  • Despite its inherent teratogenic risk, thalidomide has over the years proven to be of clinical use in a small number of mainly immunological diseases (e.g. erythema nodosum leprosum, Behçet's syndrome and rheumatoid arthritis) [27].

Analytical, diagnostic and therapeutic context of Behcet Syndrome


  1. A controlled trial of azathioprine in Behçet's syndrome. Yazici, H., Pazarli, H., Barnes, C.G., Tüzün, Y., Ozyazgan, Y., Silman, A., Serdaroğlu, S., Oğuz, V., Yurdakul, S., Lovatt, G.E. N. Engl. J. Med. (1990) [Pubmed]
  2. Treatment of Bechçet's syndrome with transfer factor. Wolf, R.E., Fudenberg, H.H., Welch, T.M., Spitler, L.E., Ziff, M. JAMA (1977) [Pubmed]
  3. Generalized myositis in Behçet disease: treatment with cyclosporine. Lingenfelser, T., Duerk, H., Stevens, A., Grossmann, T., Knorr, M., Saal, J.G. Ann. Intern. Med. (1992) [Pubmed]
  4. Thalidomide effects in Behçet's syndrome and pustular vasculitis. Jorizzo, J.L., Schmalstieg, F.C., Solomon, A.R., Cavallo, T., Taylor, R.S., Rudloff, H.B., Schmalstieg, E.J., Daniels, J.C. Arch. Intern. Med. (1986) [Pubmed]
  5. Thalidomide: current and potential clinical applications. Calabrese, L., Fleischer, A.B. Am. J. Med. (2000) [Pubmed]
  6. Behçet disease and the emergence of thalidomide. Ehrlich, G.E. Ann. Intern. Med. (1998) [Pubmed]
  7. Treatment of Behçet disease with pentoxifylline. Wolchok, J.D. Ann. Intern. Med. (1997) [Pubmed]
  8. Acyclovir and Behçet's syndrome. Resegotti, L., Pistone, M. Ann. Intern. Med. (1984) [Pubmed]
  9. Treatment of Behcet's syndrome with levamisole. de Merieux, P., Spitler, L.E., Paulus, H.E. Arthritis Rheum. (1981) [Pubmed]
  10. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. Chambers, J.C., Haskard, D.O., Kooner, J.S. J. Am. Coll. Cardiol. (2001) [Pubmed]
  11. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Travis, S.P., Czajkowski, M., McGovern, D.P., Watson, R.G., Bell, A.L. Gut (2001) [Pubmed]
  12. Concentrations of sialic acid in serum in Behçet disease. Onat, T., Eğilmez, N., Cimrin, A. Clin. Chem. (1990) [Pubmed]
  13. Determination of trace elements in blood serum of patients with Behçet disease by total reflection x-ray fluorescence analysis. Dogan, P., Dogan, M., Klockenkämper, R. Clin. Chem. (1993) [Pubmed]
  14. The critical region for Behçet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Ota, M., Mizuki, N., Katsuyama, Y., Tamiya, G., Shiina, T., Oka, A., Ando, H., Kimura, M., Goto, K., Ohno, S., Inoko, H. Am. J. Hum. Genet. (1999) [Pubmed]
  15. New variations of human CC-chemokine receptors CCR3 and CCR4. Kato, H., Tsuchiya, N., Izumi, S., Miyamasu, M., Nakajima, T., Kawasaki, H., Hirai, K., Tokunaga, K. Genes Immun. (1999) [Pubmed]
  16. The relationship of HLA-B and DR phenotypes to Behcet's syndrome, recurrent oral ulceration and the class of immune complexes. Lehner, T., Welsh, K.I., Batchelor, J.R. Immunology (1982) [Pubmed]
  17. Current concepts in the etiology and treatment of Behçet disease. Evereklioglu, C. Survey of ophthalmology. (2005) [Pubmed]
  18. Oxidative burst response to monosodium urate crystals in patients with Behçet's syndrome. Gogus, F., Fresko, I., Elbir, Y., Eksioglu-Demiralp, E., Direskeneli, H. Clin. Exp. Rheumatol. (2005) [Pubmed]
  19. Life threatening chylous pleural and pericardial effusion in a patient with Behçet's syndrome. Cöplü, L., Emrí, S., Selçuk, Z.T., Kalyoncu, F., Balkanci, F., Sahín, A.A., Bariş, Y.I. Thorax (1992) [Pubmed]
  20. Immunopathologic study of the conjunctiva in patients with behçet disease. Tugal-Tutkun, I., Urgancioglu, M., Foster, C.S. Ophthalmology (1995) [Pubmed]
  21. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Kotake, S., Higashi, K., Yoshikawa, K., Sasamoto, Y., Okamoto, T., Matsuda, H. Ophthalmology (1999) [Pubmed]
  22. 2',5'-oligoadenylate synthetase induction in lymphocytes of patients with connective tissue diseases. Hylton, W., Cayley, J., Dore, C., Denman, A.M. Ann. Rheum. Dis. (1986) [Pubmed]
  23. Neutrophil function studies in clinical medicine. Matzner, Y. Transfusion medicine reviews. (1987) [Pubmed]
  24. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Ozoran, K., Dügün, N., Gürler, A., Tutkak, H., Tokgöz, G. Scand. J. Rheumatol. (1995) [Pubmed]
  25. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Cekmen, M., Evereklioglu, C., Er, H., Inalöz, H.S., Doganay, S., Türköz, Y., Ozerol, I.H. International journal of dermatology. (2003) [Pubmed]
  26. Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome. Bacon, T.H., Ozbakir, F., Elms, C.A., Denman, A.M. Clin. Exp. Immunol. (1984) [Pubmed]
  27. Thalidomide: rationale for renewed use in immunological disorders. Schuler, U., Ehninger, G. Drug safety : an international journal of medical toxicology and drug experience. (1995) [Pubmed]
  28. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Rossi, G., Moretta, A., Locatelli, F. Blood (2004) [Pubmed]
  29. Response to intradermal injection of monosodium urate crystals in Behçet's syndrome. Cakir, N., Yazici, H., Chamberlain, M.A., Barnes, C.G., Yurdakul, S., Atasoy, S., Akcasu, A., Iscimen, A. Ann. Rheum. Dis. (1991) [Pubmed]
  30. Anti-retinal auto-antibodies in Vogt-Koyanagi-Harada syndrome, Behcet's disease, and sympathetic ophthalmia. Chan, C.C., Palestine, A.G., Nussenblatt, R.B., Roberge, F.G., Benezra, D. Ophthalmology (1985) [Pubmed]
  31. Acute phase proteins and C9 in patients with Behcet's syndrome and aphthous ulcers. Adinolfi, M., Lehner, T. Clin. Exp. Immunol. (1976) [Pubmed]
  32. Internal carotid artery dissection in a patient with Behçet's syndrome. Pannone, A., Lucchetti, G., Stazi, G., Corvi, F., Ferguson, T.L., Massucci, M., Zaccaria, A. Annals of vascular surgery. (1998) [Pubmed]
WikiGenes - Universities